Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33613, USA.
Leukemia. 2011 Jan;25(1):145-52. doi: 10.1038/leu.2010.230. Epub 2010 Oct 22.
B-cell lymphoma 6 (BCL6) and PR domain containing 1 (PRDM1) are considered as master regulators for germinal center (GC) formation and terminal B-cell differentiation. Dysregulation of BCL6 and PRDM1 has been associated with lymphomagenesis. Here, we show for the first time that direct cell-cell contact between follicular dendritic cells (FDC) and B-lymphocytes, by influencing the expression of a set of microRNAs (miRNAs), regulates the expression of BCL6 and PRDM1. We identify that, on cell adhesion to FDC, FDC induces upregulation of PRDM1 expression through downregulation of miR-9 and let-7 families and induces downregulation of BCL-6 through upregulation of miR-30 family in B-lymphocytes and lymphoma cells. We further demonstrate that the miR-30 family directly controls BCL-6 expression and miR-9-1 and let-7a directly control PRDM-1 expression through targeting their 3'UTR, mediating the FDC effect. Our studies define a novel regulatory mechanism in which the FDC, through induction of miRNAs in B-lymphocytes, orchestrates the regulation of transcription factors, promotes germinal center B-cell survival and differentiation. Dysregulation of miRNAs may interfere with B-cell survival and maturation, thus representing a novel molecular mechanism, as well as a potential therapeutic target in B-cell lymphomas.
B 细胞淋巴瘤 6(BCL6)和 PR 结构域包含 1(PRDM1)被认为是生发中心(GC)形成和终末 B 细胞分化的主要调节因子。BCL6 和 PRDM1 的失调与淋巴瘤的发生有关。在这里,我们首次表明,滤泡树突状细胞(FDC)与 B 淋巴细胞之间的直接细胞-细胞接触通过影响一组 microRNAs(miRNAs)的表达来调节 BCL6 和 PRDM1 的表达。我们发现,在细胞黏附到 FDC 上时,FDC 通过下调 miR-9 和 let-7 家族来诱导 PRDM1 表达上调,并通过上调 miR-30 家族在 B 淋巴细胞和淋巴瘤细胞中诱导 BCL-6 下调。我们进一步证明,miR-30 家族通过靶向其 3'UTR 直接控制 BCL-6 的表达,miR-9-1 和 let-7a 通过靶向其 3'UTR 直接控制 PRDM-1 的表达,介导 FDC 的作用。我们的研究定义了一种新的调节机制,其中 FDC 通过诱导 B 淋巴细胞中的 miRNAs,协调转录因子的调节,促进生发中心 B 细胞的存活和分化。miRNAs 的失调可能会干扰 B 细胞的存活和成熟,因此代表了一种新的分子机制,以及 B 细胞淋巴瘤的潜在治疗靶点。